These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
687 related articles for article (PubMed ID: 26768165)
1. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. Ramalingam SS; O'Byrne K; Boyer M; Mok T; Jänne PA; Zhang H; Liang J; Taylor I; Sbar EI; Paz-Ares L Ann Oncol; 2016 Mar; 27(3):423-9. PubMed ID: 26768165 [TBL] [Abstract][Full Text] [Related]
2. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. Ramalingam SS; Blackhall F; Krzakowski M; Barrios CH; Park K; Bover I; Seog Heo D; Rosell R; Talbot DC; Frank R; Letrent SP; Ruiz-Garcia A; Taylor I; Liang JQ; Campbell AK; O'Connell J; Boyer M J Clin Oncol; 2012 Sep; 30(27):3337-44. PubMed ID: 22753918 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer. Nishio M; Kato T; Niho S; Yamamoto N; Takahashi T; Nogami N; Kaneda H; Fujita Y; Wilner K; Yoshida M; Isozaki M; Wada S; Tsuji F; Nakagawa K Cancer Sci; 2020 May; 111(5):1724-1738. PubMed ID: 32159882 [TBL] [Abstract][Full Text] [Related]
4. Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer. Lau SCM; Batra U; Mok TSK; Loong HH Drugs; 2019 Jun; 79(8):823-831. PubMed ID: 31069718 [TBL] [Abstract][Full Text] [Related]
5. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. Ramalingam SS; Jänne PA; Mok T; O'Byrne K; Boyer MJ; Von Pawel J; Pluzanski A; Shtivelband M; Docampo LI; Bennouna J; Zhang H; Liang JQ; Doherty JP; Taylor I; Mather CB; Goldberg Z; O'Connell J; Paz-Ares L Lancet Oncol; 2014 Nov; 15(12):1369-78. PubMed ID: 25439691 [TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives. Lavacchi D; Mazzoni F; Giaccone G Drug Des Devel Ther; 2019; 13():3187-3198. PubMed ID: 31564835 [TBL] [Abstract][Full Text] [Related]
7. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Mok TS; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Lee M; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Wu YL J Clin Oncol; 2018 Aug; 36(22):2244-2250. PubMed ID: 29864379 [TBL] [Abstract][Full Text] [Related]
8. Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer. Nagano T; Tachihara M; Nishimura Y Drugs Today (Barc); 2019 Apr; 55(4):231-236. PubMed ID: 31050691 [TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). Cheng Y; Mok TS; Zhou X; Lu S; Zhou Q; Zhou J; Du Y; Yu P; Liu X; Hu C; Lu Y; Zhang Y; Lee KH; Nakagawa K; Linke R; Wong CH; Tang Y; Zhu F; Wilner KD; Wu YL Lung Cancer; 2021 Apr; 154():176-185. PubMed ID: 33721611 [TBL] [Abstract][Full Text] [Related]
10. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Mok TS; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Chawla A; Rosell R; Corral J; Migliorino MR; Pluzanski A; Noonan K; Tang Y; Pastel M; Wilner KD; Wu YL Drugs; 2021 Feb; 81(2):257-266. PubMed ID: 33331989 [TBL] [Abstract][Full Text] [Related]
12. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era? Ou SH; Soo RA Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839 [TBL] [Abstract][Full Text] [Related]
13. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Wu YL; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Tsuji F; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Nadanaciva S; Sandin R; Mok TS Lancet Oncol; 2017 Nov; 18(11):1454-1466. PubMed ID: 28958502 [TBL] [Abstract][Full Text] [Related]
14. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Reckamp KL; Giaccone G; Camidge DR; Gadgeel SM; Khuri FR; Engelman JA; Koczywas M; Rajan A; Campbell AK; Gernhardt D; Ruiz-Garcia A; Letrent S; Liang J; Taylor I; O'Connell JP; Jänne PA Cancer; 2014 Apr; 120(8):1145-54. PubMed ID: 24501009 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials. Zhang Y; Zhang Z; Huang X; Kang S; Chen G; Wu M; Miao S; Huang Y; Zhao H; Zhang L Clin Lung Cancer; 2017 Sep; 18(5):e333-e340. PubMed ID: 28462807 [TBL] [Abstract][Full Text] [Related]
17. A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer. Kelly RJ; Shepherd FA; Krivoshik A; Jie F; Horn L Ann Oncol; 2019 Jul; 30(7):1127-1133. PubMed ID: 31070709 [TBL] [Abstract][Full Text] [Related]
18. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Wu YL; Zhou C; Liam CK; Wu G; Liu X; Zhong Z; Lu S; Cheng Y; Han B; Chen L; Huang C; Qin S; Zhu Y; Pan H; Liang H; Li E; Jiang G; How SH; Fernando MCL; Zhang Y; Xia F; Zuo Y Ann Oncol; 2015 Sep; 26(9):1883-1889. PubMed ID: 26105600 [TBL] [Abstract][Full Text] [Related]
19. REPORT- Clinical outcomes of using second - versus first-Generation EGFR-tkis for the First-Line treatment of advanced NSCLC patients with EGFR mutations: A meta-analysis. Hou B; Lu X; Gao DC; Liu QX; Zhou D; Zheng H; Dai JG Pak J Pharm Sci; 2021 Jul; 34(4):1459-1468. PubMed ID: 34799322 [TBL] [Abstract][Full Text] [Related]
20. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Zhou C; Wu YL; Chen G; Feng J; Liu XQ; Wang C; Zhang S; Wang J; Zhou S; Ren S; Lu S; Zhang L; Hu C; Hu C; Luo Y; Chen L; Ye M; Huang J; Zhi X; Zhang Y; Xiu Q; Ma J; Zhang L; You C Ann Oncol; 2015 Sep; 26(9):1877-1883. PubMed ID: 26141208 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]